Navigation Links
Yongye Biotechnology International, Inc. Appoints New Independent Auditor

BEIJING, July 10 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology International, Inc. ("Yongye" or the "Company") (OTC Bulletin Board: YGYB), a leading distributor of plant and animal nutrients headquartered in Beijing, PRC, announced today it has engaged MSPC Certified Public Accountants and Advisors, P.C. as the Company's independent auditor.

The Company has engaged MSPC Certified Public Accountants and Advisors, P.C. ("MSPC") to serve as the Company's independent auditor effective immediately. MSPC was founded in 1944 and provides traditional accounting services to a wide range of companies, from emerging entrepreneurial ventures to large, publicly held entities. MSPC is an active member in Moore Stephens North America and Moore Stephens International Limited, a network of leading, independently owned and operated accounting and consulting firms. MSPC enjoys wide representation in all metropolitan areas in the United States as well as worldwide. MSPC is regarded as one of the world's top twenty accounting and consulting networks with more than 316 independently owned and operated member firms. There are 539 offices in 93 countries throughout the world including Hong Kong and China. It has 15,404 principals and staff.

About Yongye Biotechnology, Inc.

Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the domestic distribution and sales of fulvic acid based nutritional compounds for plants and animals. The Company's patent pending process and proprietary formulas allow it to create products which increase the yields in crop production and improve livestock health. The Company sells its products to distributors and farmers located in ten provinces across China including: Xinjiang, Hebei, Inner Mongolia, Gansu, Hubei, Shandong, Anhui, Jiangsu, Yunan, and Guangdong.


Certain statements set forth in this press release constitute "Forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. All such forward-looking statements involve risks and uncertainties, including, but not limited to: statements regarding the Company's products; marketing and sales; patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with other companies. There can be no assurance that such forward-looking statements will prove to be accurate and Yongye undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.

For more information, please contact:

Yongye Biotechnology International, Inc.

Larry Gilmore

Vice President of Corporate Strategy

Tel: +86-10-8232-8866 x8880

Fax: +86-10-8231-1797


SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
2. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
3. Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video
4. N.C. Biotechnology Center Launches Industrial Fellowship Program
5. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
6. In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study
7. Pharsight to Present on Literature-Based Disease Modeling Approaches at AAPS National Biotechnology Conference
8. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
9. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
10. Gen-Probe to Webcast Presentation at Seventh Annual Needham Biotechnology and Medical Technology Conference
11. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
Post Your Comments:
(Date:11/30/2015)... Epigenetics Corp. ("Zenith" or the "Company") today announced that it ... Board of Directors to replace Dr. Peter Johann . ... as co-founder of Resverlogix, with expertise in the fields of ... --> Dr. Wong remarked, "I am very excited to ... expertise in epigenetics and the advanced stage of the R&D ...
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine Exhibitions and Universal Partnerships ... opening in March 2016 at Melbourne Museum in Melbourne, Australia. Immediately following the ... American tour dates. The Exhibition is based on Universal Pictures’ Jurassic World, one ...
(Date:11/30/2015)... 2015 Human Longevity, Inc. (HLI), the genomics-based, ... Cypher Genomics, Inc., a leading genome informatics company offering ... solutions. The San Diego -based company ... CEO and Co-founder, Ashley Van Zeeland , Ph.D., who ... details of the deal were not disclosed. ...
(Date:11/30/2015)... , Nov. 30, 2015  HUYA Bioscience International, ... China,s pharmaceutical innovations, today announced it has ... Development Fund (KDDF) to foster collaboration between KDDF and ... and commercialization of healthcare products for the global market. ... an important source of new innovative preclinical and clinical ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):